Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type

Website (34)

Journal Article (20)

Booklet (13)

Guidelines (13)

Fact Sheet (10)

Video (6)

Palm Card (6)

Consensus Recommendations (4)

Worksheet (3)

Referral Form (3)

Webinar (2)

Filter By Resource Library: Topic

Assess (113)

Implement the Initiative (107)

Learn (107)

Prepare the Care Team (101)

Patient Education (64)

B-cell ALL (54)

Lay the Groundwork (50)

Multiple Myeloma (50)

CLL (42)

MRD Testing Methods (24)

Treatment Decision-Making (21)

Financial Resources (16)

Timing of MRD Testing (8)

Clinical Trials (8)

Treatment (7)

Social & Emotional Support (6)

Act (6)

Evaluate Your Progress (6)

Evaluation (6)

MRD Testing Facilities (6)

Resource Library Search

You searched for:

Assess

Displaying results 81 - 100 of 113

Patient Assistance & Reimbursement Guide

Find the most up-to-date information on oncology assistance and reimbursement programs by searching for a prescribed product or company name, then further streamline your search by applying coverage and assistance-type filters. Access details on all available financial assistance and reimbursement program benefits, application information, and eligibility criteria. Listings include direct links to external websites and company phone numbers and will be updated in real-time, so you�ll always have access to the latest information and external program links. The digital Guide links directly to the ICD-10 codes website and the Library of NCCN Compendia for current indications. These resources were identified by ACCC members as the most up-to-date and authoritative source for this information.

Association of Community Cancer Centers (ACCC)

Assess B-cell ALL CLL Financial Resources Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Patient Education Prepare the Care Team Website

Financial Advocacy Network

The Financial Advocacy Network's tools and resources empower providers to proactively integrate financial health into the oncology care continuum and help patients gain access to high-quality care for a better quality of life.

Association of Community Cancer Centers (ACCC)

Assess B-cell ALL CLL Financial Resources Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Website

ARUP Laboratories

ARUP offers MRD testing for ALL and other blood cancers.

ARUP Consult

Assess B-cell ALL Implement the Initiative Learn MRD Testing Facilities Prepare the Care Team Website

Elements of an Evaluation Plan

This websites provides key elements of an evaluation plan, which can help guide your evaluation efforts.

Agency for Healthcare Research and Quality (AHRQ)

Act Assess Evaluate Your Progress Evaluation Prepare the Care Team Website

The Impact of Minimal Residual Disease in Acute Lymphoblastic Leukemia

This webcast provides an overview of treatment options for patients living with ALL, MRD testing, clinical trials, and the importance of open communication with the healthcare team.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL Implement the Initiative Learn MRD Testing Methods Patient Education Prepare the Care Team Webinar

Testing for Minimal Residual Disease

This three minute video provides an overview of MRD and MRD testing options.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Learn MRD Testing Methods Multiple Myeloma Patient Education Prepare the Care Team Video

Personalized Medicine Video Series

This video series aims to answer many questions that patients may have about lab and imaging tests.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Learn Multiple Myeloma Patient Education Video

The Leukemia and Lymphoma Society's Patient Referral Form

By completing this form, your patient will be contacted by a LLS Information Specialist. Information Specialists are social workers, nurses and health educators with expertise in blood cancers who provide personalized support to patients, caregivers, and families.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Patient Education Prepare the Care Team Referral Form

Personalized Support

This palm card provides a list of support services offered by LLS.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Implement the Initiative Learn Multiple Myeloma Patient Education Prepare the Care Team Social & Emotional Support Palm Card

Help with Finances

This palm card provides an overview of financial assistance programs offered by LLS.

The Leukemia and Lymphoma Society (LLS)

Assess B-cell ALL CLL Financial Resources Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Patient Education Prepare the Care Team Palm Card

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

This review article presents "the work of an international, multidisciplinary, 174-member panel convened to identify critical questions on key issues pertaining to MRD in chronic lymphocytic leukemia, review evaluable data, develop unified answers in conjunction with local expert input, and provide recommendations for future studies. Recommendations are presented regarding methodology for MRD determination, assay requirements and in which tissue to assess MRD, timing and frequency of assessment, use of MRD in clinical practice versus clinical trials, and the future usefulness of MRD assessment.

Leukemia

Assess Clinical Trials CLL Implement the Initiative Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL

Detection of MRD in CLL is becoming increasingly important as treatments improve...There was good correlation between four-CLR and six-CLR panels in dilution studies and clinical samples, with 100% concordance for detection of residual disease at the 0.01% (10?4) level (n=59) and good linearity even at the 0.001�0.01% (10?5�10?4) level. A six-CLR panel therefore provides equivalent results to the four-CLR panel but it requires fewer reagents, fewer cells and a much simpler analysis approach.

Leukemia

Assess CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Journal Article

A complementary role of multiparameter flow cytometry and high-throughput sequencing for minimal residual disease detection in chronic lymphocytic leukemia: an European Research Initiative on CLL study

In CLL the level of MRD after therapy is an independent predictor of outcome�A parallel analysis of high-throughput sequencing using the ClonoSEQ assay showed good concordance with flow cytometry results at the 0.010% (10(-4)) level, the MRD threshold defined in the 2008 International Workshop on CLL guidelines, but it also provides good linearity to a detection limit of 1 in a million (10(-6)). The combination of both technologies would permit a highly sensitive approach to MRD detection while providing a reproducible and broadly accessible method to quantify residual disease and optimize treatment in CLL.

Leukemia

Assess CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Journal Article

Measurable residual disease in multiple myeloma: ready for clinical practice?

The landscape of multiple myeloma has changed considerably in the past two decades regarding new treatments, insight into disease biology and innovation in the techniques available to assess MRD as the most accurate method to evaluate treatment efficacy. The sensitivity and standardization achieved by these techniques together with unprecedented rates of CR induced by new regimens, raised enormous interest in MRD as a surrogate biomarker of patients� outcome and endpoint in clinical trials. By contrast, there is reluctance and general lack of consensus on how to use MRD outside clinical trials. Here, we discuss critical aspects related with the implementation of MRD in clinical practice.

Journal of Hematology & Oncology

Assess Clinical Trials Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Minimal residual disease in multiple myeloma: why, when, where

We review the data supporting MRD testing as well as its limitations and how it may fit in with current and future clinical practice.

Hematology

Assess Implement the Initiative Learn Multiple Myeloma Prepare the Care Team Timing of MRD Testing Journal Article

Minimal residual disease assessment in multiple myeloma patients: minimal disease with maximal implications

This review examines the different methods used to detect MRD and discusses future considerations regarding the implementation in day-to-day clinical practice and as a prospective primary endpoint for clinical trials.

Frontiers in Oncology

Assess Clinical Trials Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Multiple Myeloma Prepare the Care Team Journal Article

The evolving use of minimal residual disease (MRD) assessment in chronic lymphocytic leukemia

"This monograph examines clinical trial data regarding the role of MRD in CLL, and provides recommendations on how to incorporate MRD assessment into clinical management."

Clinical Advances in Hematology & Oncology

Assess Clinical Trials CLL Implement the Initiative Lay the Groundwork Learn MRD Testing Methods Prepare the Care Team Timing of MRD Testing Treatment Decision-Making Journal Article

Best practices for the assessment of measurable residual disease (MRD) in multiple myeloma

Based on available evidence correlating attainment of MRD negativity with outcomes, MRD assessment has been incorporated into ongoing clinical trials. Analyses will provide additional insight into the correlation between MRD and outcome. This monograph examines the available trial data and provides recommendations on how to incorporate MRD assessment into clinical management.

Clinical Advances in Hematology & Oncology

Assess Implement the Initiative Learn MRD Testing Methods Prepare the Care Team Journal Article

Role of allogeneic stem cell transplantation in adult patients with Ph-negative acute lymphoblastic leukemia

This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy.

Blood

Assess B-cell ALL Implement the Initiative Learn Prepare the Care Team Treatment Decision-Making Journal Article

NCCN Guidelines for Multiple Myeloma

NCCN offers clinical guidelines to guide the treatment and care of patients with multiple myeloma. (Create a free account profile to access guidelines.)

National Comprehensive Cancer Network (NCCN)

Assess Implement the Initiative Lay the Groundwork Learn Multiple Myeloma Prepare the Care Team Treatment Treatment Decision-Making Guidelines

Displaying results 81 - 100 of 113

Share

In This Section

Resource Library Search Filter

Resource Library Search

Share

In This Section

Resource Library Search Filter

Resource Library Search

Sharing Article: